CA3143496A1 - Ectonucleotidase inhibitors and methods of use thereof - Google Patents

Ectonucleotidase inhibitors and methods of use thereof Download PDF

Info

Publication number
CA3143496A1
CA3143496A1 CA3143496A CA3143496A CA3143496A1 CA 3143496 A1 CA3143496 A1 CA 3143496A1 CA 3143496 A CA3143496 A CA 3143496A CA 3143496 A CA3143496 A CA 3143496A CA 3143496 A1 CA3143496 A1 CA 3143496A1
Authority
CA
Canada
Prior art keywords
compound
cancer
amino
img
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143496A
Other languages
English (en)
French (fr)
Inventor
Lijing Chen
Roland Joseph Billedeau
Jim Li
Timothy Friend Stanton
Original Assignee
Antengene Therapeutics Ltd
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Therapeutics Ltd, Calithera Biosciences Inc filed Critical Antengene Therapeutics Ltd
Publication of CA3143496A1 publication Critical patent/CA3143496A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3143496A 2019-06-20 2020-06-18 Ectonucleotidase inhibitors and methods of use thereof Pending CA3143496A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864031P 2019-06-20 2019-06-20
US62/864,031 2019-06-20
PCT/US2020/038395 WO2020257429A1 (en) 2019-06-20 2020-06-18 Ectonucleotidase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3143496A1 true CA3143496A1 (en) 2020-12-24

Family

ID=74040909

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143496A Pending CA3143496A1 (en) 2019-06-20 2020-06-18 Ectonucleotidase inhibitors and methods of use thereof

Country Status (8)

Country Link
US (1) US20220363709A1 (enExample)
EP (1) EP3986894A4 (enExample)
JP (1) JP2022537358A (enExample)
KR (1) KR20220024629A (enExample)
CN (1) CN114008048A (enExample)
AU (1) AU2020294724A1 (enExample)
CA (1) CA3143496A1 (enExample)
WO (1) WO2020257429A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
IL304348B2 (en) 2018-04-30 2024-08-01 Oric Pharmaceuticals Inc CD73 inhibitors
SG11202012001YA (en) 2018-06-21 2021-01-28 Calithera Biosciences Inc Ectonucleotidase inhibitors and methods of use thereof
JP7557522B2 (ja) 2019-07-16 2024-09-27 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
PL4051688T3 (pl) 2019-10-30 2025-09-22 Oric Pharmaceuticals, Inc. Inhibitory cd73
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
KR102775989B1 (ko) * 2022-11-01 2025-03-04 윤주호 콜치신과 메트포르민을 유효성분으로 하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
MA39986A (fr) * 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
EP3510040A4 (en) * 2016-09-09 2020-06-03 Calithera Biosciences, Inc. EKTONUCLEOTIDASE INHIBITORS AND METHOD FOR USE THEREOF
KR102638592B1 (ko) * 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
SG11202012001YA (en) * 2018-06-21 2021-01-28 Calithera Biosciences Inc Ectonucleotidase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
JP2022537358A (ja) 2022-08-25
US20220363709A1 (en) 2022-11-17
EP3986894A4 (en) 2023-08-09
AU2020294724A1 (en) 2022-01-20
CN114008048A (zh) 2022-02-01
EP3986894A1 (en) 2022-04-27
WO2020257429A1 (en) 2020-12-24
KR20220024629A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
CA3143496A1 (en) Ectonucleotidase inhibitors and methods of use thereof
US11208414B2 (en) Ectonucleotidase inhibitors and methods of use thereof
US11034715B2 (en) Ectonucleotidase inhibitors and methods of use thereof
CA3104088A1 (en) Ectonucleotidase inhibitors and methods of use thereof
WO2025073290A1 (en) Vps4 inhibitors and methods of use thereof
WO2026073439A1 (en) Vps4 inhibitors and methods of use thereof
BR112019012327B1 (pt) Composto inibidor de ectonucleotidase, composição farmacêutica que compreende o mesmo, método in vitro de inibição de cd73 em uma célula e uso do dito composto para o tratamento de câncer
EA039042B1 (ru) Ингибиторы эктонуклеотидазы и способы их применения
HK40013556B (en) Ectonucleotidase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240805